Literature DB >> 24863842

Clotrimazole as a pharmaceutical: past, present and future.

P D Crowley1, H C Gallagher.   

Abstract

Clotrimazole is a broad-spectrum antimycotic drug mainly used for the treatment of Candida albicans and other fungal infections. A synthetic, azole antimycotic, clotrimazole is widely used as a topical treatment for tinea pedis (athlete's foot), as well as vulvovaginal and oropharyngeal candidiasis. It displays fungistatic antimycotic activity by targeting the biosynthesis of ergosterol, thereby inhibiting fungal growth. As well as its antimycotic activity, clotrimazole has become a drug of interest against several other diseases such as sickle cell disease, malaria and some cancers. It has also been combined with other molecules, such as the metals, to produce clotrimazole complexes that show improved pharmacological efficacy. Moreover, several new, modified-release pharmaceutical formulations are also undergoing development. Clotrimazole is a very well-tolerated product with few side effects, although there is some drug resistance appearing among immunocompromised patients. Here, we review the pharmaceutical chemistry, application and pharmacology of clotrimazole and discuss future prospects for its further development as a chemotherapeutic agent.
© 2014 The Society for Applied Microbiology.

Entities:  

Keywords:  antifungals; antimicrobials; formulation; mycology; pharmaceuticals; pharmaceutics; pharmacology; resistance

Mesh:

Substances:

Year:  2014        PMID: 24863842     DOI: 10.1111/jam.12554

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  22 in total

1.  [Clotrimazole and ciclopirox olamine respectively in combination with methylprednisolone aceponate as extemporaneous formulations].

Authors:  J Wohlrab; R H H Neubert; E Sommer; J Michael
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

Review 2.  An epigrammatic status of the 'azole'-based antimalarial drugs.

Authors:  Mousmee Sharma; Parteek Prasher
Journal:  RSC Med Chem       Date:  2019-12-23

3.  Implementing Spanlastics for Improving the Ocular Delivery of Clotrimazole: In vitro Characterization, Ex vivo Permeability, Microbiological Assessment and In vivo Safety Study.

Authors:  Manar Adel Abdelbari; Shereen Sameh El-Mancy; Ahmed Hassen Elshafeey; Aly Ahmed Abdelbary
Journal:  Int J Nanomedicine       Date:  2021-09-10

4.  A chloroacetamide derivative as a potent candidate for fusariosis treatment.

Authors:  Gabriella da Rosa Monte Machado; Stefânia Neiva Lavorato; William Lopes; Marilene Henning Vainstein; Mário Lettieri Teixeira; Ricardo José Alves; Saulo Fernandes de Andrade; Alexandre Meneghello Fuentefria
Journal:  Braz J Microbiol       Date:  2022-06-01       Impact factor: 2.214

5.  The roles of potassium channels in contractile response to urotensin-II in mercury chloride induced endothelial dysfunction in rat aorta.

Authors:  A H Ahmed; I M Maulood
Journal:  Iran J Vet Res       Date:  2018       Impact factor: 1.376

6.  Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Authors:  Tianying Duan; Onur Cil; Jay R Thiagarajah; Alan S Verkman
Journal:  JCI Insight       Date:  2019-02-21

7.  In vitro combination therapy using low dose clotrimazole and photodynamic therapy leads to enhanced killing of the dermatophyte Trichophyton rubrum.

Authors:  C Oliver Morton; Mousawi Chau; Colin Stack
Journal:  BMC Microbiol       Date:  2014-10-15       Impact factor: 3.605

8.  Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa.

Authors:  Francesca D'Angelo; Valerio Baldelli; Nigel Halliday; Paolo Pantalone; Fabio Polticelli; Ersilia Fiscarelli; Paul Williams; Paolo Visca; Livia Leoni; Giordano Rampioni
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2.

Authors:  Catarina Costa; Jonathan Ribeiro; Isabel M Miranda; Ana Silva-Dias; Mafalda Cavalheiro; Sofia Costa-de-Oliveira; Acácio G Rodrigues; Miguel C Teixeira
Journal:  Front Microbiol       Date:  2016-04-19       Impact factor: 5.640

Review 10.  Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration.

Authors:  Shahida A Khan; Ghazi Damanhouri; Ashraf Ali; Sarah A Khan; Aziz Khan; Ahmed Bakillah; Samy Marouf; Ghazi Al Harbi; Saeed H Halawani; Ahmad Makki
Journal:  Nutr Metab (Lond)       Date:  2016-08-08       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.